{"podcast":{"title":"Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology","slug":"weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980","podcast_index_feed_id":7345980,"rss_url":"https://anchor.fm/s/ff5a3958/podcast/rss","website_url":"https://podcasters.spotify.com/pod/show/amer-ghavanini","image_url":"https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/42741030/42741030-1735440401368-ad7d63bca66f6.jpg","author":"Amer Ghavanini","episode_count":207,"summary":"A selection of recent neurology papers is summarized and discussed, with a focus on review articles and those that have the potential to change clinical practice. Please note that AI has been used in generating the content.","last_synced_at":"2026-07-07T06:17:21.772797+00:00","page_url":"https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980"},"episode":{"title":"Tavapadon as Adjunctive Therapy for Parkinson Disease - TEMPO-3 Trial","slug":"tavapadon-as-adjunctive-therapy-for-parkinson-disease-tempo-3-trial","published_at":"2026-05-24T16:15:34+00:00","page_url":"https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/tavapadon-as-adjunctive-therapy-for-parkinson-disease-tempo-3-trial","show_page_url":"https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980","url":"https://podcasters.spotify.com/pod/show/amer-ghavanini/episodes/Tavapadon-as-Adjunctive-Therapy-for-Parkinson-Disease---TEMPO-3-Trial-e3jr15e","audio_url":"https://anchor.fm/s/ff5a3958/podcast/play/120472174/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-24%2F0f51477e-41bb-9b98-c158-1436898f7771.m4a","summary":"The provided sources detail phase 3 clinical trial results for tavapadon , a novel, once-daily dopamine D1/D5 receptor agonist designed to treat Parkinson disease . In the TEMPO-1 study, fixed doses of the medication significantly improved motor function and daily living experiences for patients in the early stages of the disease. Simultaneously, the TEMPO-3 trial demonstrated that tavapadon effectively increases "good-on-time" and reduces daily "off-time" when used as an add-on therapy for patients experiencing fluctuations while on levodopa . Researchers observed that the drug's selective targeting of specific receptors aims to minimize the side effects , such as hallucinations or impulse control issues, often linked to traditional dopamine agonists. Across both studies, tavapadon maintained a favorable safety profile , with most adverse events being mild to moderate in severity. These findings suggest that tavapadon offers a clinically meaningful new option for managing symptoms throughout different phases of the condition.","meta_description":"The provided sources detail phase 3 clinical trial results for tavapadon , a novel, once-daily dopamine D1/D5 receptor agonist designed to treat Parkinson…","key_points":[],"chapters":[],"topics":[],"duration_seconds":970,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/episodes/tavapadon-as-adjunctive-therapy-for-parkinson-disease-tempo-3-trial/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/tavapadon-as-adjunctive-therapy-for-parkinson-disease-tempo-3-trial.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}